On 22nd of September we changed our brand name from TBD-Biodiscovery to TBD Pharmatech. The legal name will remain TBD-Biodiscovery Ltd. The change of the name means a new logo with a fresh visual identity…
Read more
First Foray into Disc Golf In September last year, TBD Pharmatech plunged into the unfamiliar world of disc golf. Our debut team – Sander Kotkas, Jürgen Vahter, and Merle Muruvee – represented…
Read moreThe project aims to develop a new, more effective technology for synthesizing an active pharmaceutical ingredient (API) for a drug used primarily as a pain reliever for moderate to severe pain. The…
Read more
On March 20, 2023, TBD Pharmatech proudly hosted the bright minds of BÜS – a student organization from Tartu University that unites natural sciences students. BÜS aims to empower future biologists…
Read more
TBD Pharmatech is excited to announce that we will be attending CPHI North America 2023, one of the most important events in the pharmaceutical industry. Our Chief Business Officer, Olga Tšubrik, will…
Read more
March 20-23 2023 TBD Pharmatech will be present at DCAT Week 2023! This is the first time TBD Pharmatech is attending DCAT Week. We are already looking forward to discuss CDMO collaboration! Book a…
Read more
Inactive pharmaceutical ingredients (IPIs) are ingredients found in medication that do not directly affect the treatment of a disease or condition. While they may not be active, these components can…
Read more
TBD Pharmatech (formerly TBD-Biodiscovery) specialises in Active Pharmaceutical Ingredients (API), advanced intermediates, and the development and production of fine chemicals.
